Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion
Aura Biosciences announced the appointment of Natalie Holles as CEO and President, coinciding with the nearing completion of patient enrollment in its pivotal Phase 3 CoMpass trial for belzupacap sarotalocan (bel-sar), a potential first frontline, vision-preserving therapy for early choroidal melanoma. The company maintains guidance for enrollment …